Abstract
Background A growing body of work suggests that inherited genetic variants can be utilized as non-invasive biomarkers to predict cancer-specific patient outcomes and guide therapy after resection of pancreatic ductal adenocarcinoma (PDAC). Specifically, two recent retrospective analyses led to the identification and retrospective validation of three single nucleotide polymorphisms (SNPs) in the CD44 and CHI3L2 genes (SNPrs187115, SNPrs353630, SNPrs684559) genes that can serve as predictive biomarkers to help select patients who are likely to benefit from pancreatic resection. Those SNPs have been shown to associate with an over 2-fold increased risk for tumour-related death in three independent PDAC study cohorts from Europe and the U.S (Hazard ratio (HR) up-to 0.38; p-value up-to 1x10−8).
Methods In order to translate these retrospective findings into clinical practice, we aim to utilise a cohort of PDAC patients who undergo pancreatic resection in three hospitals in Switzerland to prospectively validate the association of the identified SNPs in the CD44 and CHI3L2 genes with PDAC survival after resection in a controlled clinical setting. All patients with a histopathological diagnosis of PDAC who undergo pancreatic resection and fulfil the inclusion criteria will be included consecutively. The SNP genotypes will be determined using standard genotyping techniques from patient blood samples. For each genotyped locus, log-rank and Cox multivariate regression tests will be performed, accounting for the relevant covariates AJCC-stage and resection-status. Clinical follow-up data will be collected for at least 3 years. Sample size calculation resulted in a number of 150 patients (80% power to detect allelic differences in survival; effect size>2.0 between genotypes; two-sided α-level of 0.05; drop-out rate of 10%; potential additional error margin of 10%).
Discussion This is the first prospective study of the CD44 and CHI3L2 gene SNP-based biomarker signature in PDAC. A prospective validation of these biomarkers would enable its utilization as a non-invasive, predictive signature of survival after pancreatic resection that is readily available at the time of PDAC diagnosis. The results of this study may lead to improved patient outcomes in resectable PDAC.
Trial registration Not listed in a registry, because no results of a health care intervention are reported.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Kantonale Ethikkommission Zurich gave ethical approval for this work(BASEC-Nr. 2019-00178)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors